Regulatory Significance 6/10

Blood Collection Tubes as Unrecognised IVD Variables: A Framework for Laboratory Verification and Validation

This review highlights blood collection tubes as an under-recognised preanalytical variable that can introduce clinically significant assay interference. The authors present a structured verification and validation framework for laboratories evaluating new tube types, covering additive effects, analyte stability, and regulatory requirements across the US, EU, and Canada. Proper BCT validation can prevent incorrect results, unnecessary repeat testing, and patient harm.

The original study

Blood collection tubes as medical devices: The potential to affect assays and proposed verification and validation processes for the clinical laboratory.

Authors
Bowen RA, Adcock DM
Journal
Clinical biochemistry
Type
Journal Article, Review, Validation Study
PMID
27765677
Read the original study →

Original abstract

Blood collection tubes (BCTs) are an often under-recognized variable in the preanalytical phase of clinical laboratory testing. Unfortunately, even the best-designed and manufactured BCTs may not work well in all clinical settings. Clinical laboratories, in collaboration with healthcare providers, should carefully evaluate BCTs prior to putting them into clinical use to determine their limitations and ensure that patients are not placed at risk because of inaccuracies due to poor tube performance. Selection of the best BCTs can be achieved through comparing advertising materials, reviewing the literature, observing the device at a scientific meeting, receiving a demonstration, evaluating the device under simulated conditions, or testing the device with patient samples. Although many publications have discussed method validations, few detail how to perform experiments for tube verification and validation. This article highlights the most common and impactful variables related to BCTs and discusses the validation studies that a typical clinical laboratory should perform when selecting BCTs. We also present a brief review of how in vitro diagnostic devices, particularly BCTs, are regulated in the United States, the European Union, and Canada. The verification and validation of BCTs will help to avoid the economic and human costs associated with incorrect test results, including poor patient care, unnecessary testing, and delays in test results. We urge laboratorians, tube manufacturers, diagnostic companies, and other researchers to take all the necessary steps to protect against the adverse effects of BCT components and their additives on clinical assays.